🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "significant breakthrough" in the battle against superbug strains of the pathogen, according to researchers.

An International Health Concern

Cases of gonorrhoea are on the rise globally, with estimates suggesting over 82 million new cases per year. Notably increased rates are observed in the African continent and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune advancement in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Health officials are deeply concerned about the surge in treatment-resistant strains. The World Health Organization has classified it as a "priority pathogen". A tracking program showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Receive Authorization

Zoliflodacin, marketed under the name Nuzolvence, was approved by the American regulatory agency in mid-December for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Researchers believe that specific application of this new drug will help hinder the development of resistance.

Another new antibiotic, created by the drugmaker GSK, gained clearance in close succession. This medication, which is employed against UTIs, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a innovative non-profit model for drug creation. The charitable organization GARDP collaborated with the drug firm its industry partner to bring it to fruition.

“This authorization represents a huge turning point in the management of multidrug-resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Testing Outcomes and Global Access

Based on results detailed in a major medical journal, zoliflodacin successfully treated more than 90% of cases of the STI. This puts it on an similar efficacy with the existing first-line therapy, which uses two antibiotics. The trial enrolled over 900 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the authority to license and sell the drug in a wide range of developing nations.

Clinicians on the front lines have shared hope. The availability of a single-dose, oral treatment of this kind is hailed as a "game-changer" for managing the epidemic. This is viewed as essential to alleviate the strain of the illness for individuals and to stop the proliferation of highly drug-resistant gonorrhoea globally.